Copy Link Print Information

Trastuzumab emtansine (solution)

(Synonyms: Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution))
7 Cited Publications
Customer Review

Based on 7 publication(s) in Google Scholar

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer.

For research use only. We do not sell to patients.

  • Purity: 98.27%
  • CAS No.: 1018448-65-1
  • Molecular Weight:149114 (average)
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Trastuzumab emtansine (solution) Chemical Structure
    Trastuzumab emtansine (solution) Chemical Structure
  • Experimental Validation Results for Trastuzumab emtansine (solution)
  • Experimental Validation Results for Trastuzumab emtansine (solution)
  • Experimental Validation Results for Trastuzumab emtansine (solution)
  • Experimental Validation Results for Trastuzumab emtansine (solution)
  • Experimental Validation Results for Trastuzumab emtansine (solution)
CAS No.: 1018448-65-1
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Trastuzumab emtansine (solution):

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Trastuzumab emtansine (solution)

More
Customer Validation & Images
Cell Proliferation/Viability AssayFlow CytometryIn Vivo Efficacy StudyIn Vivo ImagingIHC
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • In Vivo Imaging
  • IHC
  • Flow Cytometry

All EGFR Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Trastuzumab emtansine (solution) Chemical Structure
    Trastuzumab emtansine (solution) Chemical Structure
    1/16
  • 1/16

    Trastuzumab emtansine (solution) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Apr;11(13):e2306309. [Abstract]

    Customer Validation
     Trastuzumab emtansine (T-DM1; 0.001-10 nM; 5 days). In vitro evaluation of ADCs. Proliferation inhibitory activity of ADCs against NCI‐N87 (HER2+) cells. Tumor cells were treated with ADCs for 5 days and relative cell viability (%) was calculated.

  • 1/16

    Trastuzumab emtansine (solution) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Apr;11(13):e2306309. [Abstract]

    Customer Validation
     Trastuzumab emtansine (T-DM1; 5 mg/kg; intraperitoneal injection). The tumor volume change of bystander killing in co-inoculation xenograft model following a single intravenous ADC dose of 2 or 5 mg/kg.

  • 1/16

    Trastuzumab emtansine (solution) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Apr;11(13):e2306309. [Abstract]

    Customer Validation
     Trastuzumab emtansine (T-DM1; 5 mg/kg; intraperitoneal injection). Bystander killing in co-inoculation xenograft model following a single intravenous ADC dose of 2 or 5 mg/kg. Bioluminescence imaging data of luciferase activity.

  • 1/16

    Trastuzumab emtansine (solution) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Apr;11(13):e2306309. [Abstract]

    Customer Validation
     Trastuzumab emtansine (T-DM1; 5 mg/kg; intraperitoneal injection). HER2 expression on tumors consisting of either HER2‐positive or HER2‐negative cells, co‐inoculation (2: 5 ratio at the time of implantation) and the remaining and regrown tumors after treatment with each ADC.

  • 1/16

    Trastuzumab emtansine (solution) purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2024 Sep 8;16(9):1189. [Abstract]

    Customer Validation
     FACS analysis of ET-NK/T-DM1. ED-TM at 20 μg was added to NK cells to prepare ET-NK cells for 12 h at 37 ℃ and 5% CO2. The ET-NK cells were mixed with T-DM1 at 20 μg for 15 min at room temperature, resulting in the formation of ET-NK/T-DM1. ED-TM and T-DM1 were conjugated with rhodamine and FITC, respectively. Fluorescence on the ET-NK/T-DM1 was observed using CLSM. ED-TM: cell surface engineering fusion protein; T-DM1: trastuzumab emtansine; ET-NK: NK cell modified by ED-TM; ET-NK/T-DM1: ET-NK cell incorporated with T-DM1; FITC: fluorescein; CLSM: confocal laser scanning microscopy.

  • Trastuzumab emtansine (solution)